Abstract. Protein C activation by thrombin is significantly accelerated by the endothelial cell surface protein thrombomodulin, Factor Va, or its light chain. In this study we have compared the activation of protein C in the presence of either cofactor and examined the possibility that thrombomodulin and Factor Va-light chain act together to regulate protein C activation by thrombin. At all concentrations ofprotein C used, thrombomodulin was 20 times more efficient than Factor Va-light chain in accelerating protein C activation by thrombin. Protein C treated with chymotrypsin to remove the amino-terminal 41 amino acids that contain the y-carboxyglutamyl residues was activated by the thrombin-thrombomodulin complex at an identical rate to native protein C, whereas the modified protein C was activated by Factor Va-light chain and thrombin at only 5% of the rate obtained by using native protein C. Increasing concentrations ofFactor Va-light chain, .30 nM, inhibited thrombin-thrombomodulin catalyzed protein C activation with complete inhibition observed at 90 nM Factor Va-light chain. On the other hand, increasing thrombomodulin concentrations did not inhibit protein C activation by Factor Valight chain and thrombin. These reactions in solution mimic, in part, those obtained on endothelial cells where protein C lacking the y-carboxyglutamyl domain is activated poorly and Factor Va-light chain at concentrations greater than 50 nM inhibited the activation of native Dr. C. T. Esmon is an Established Investigator of the American Heart Association.
Introduction
Two different cofactors have been found to accelerate the rate of protein C activation by thrombin: (a) the endothelial cell surface protein thrombomodulin (1, 2) , and (b) the coagulation protein Factor Va (3, 4) . Thrombomodulin forms an equimolar complex with thrombin, thereby altering the catalytic properties of thrombin (5) . In this complex, thrombin fails to clot fibrinogen, activate platelets, or cleave Factor V, whereas its ability to activate protein C is enhanced nearly 1,000-fold. Protein C treated with chymotrypsin to remove the amino-terminal 41 amino acids, which includes all of the y-carboxyglutamic acid residues (gla-domainless protein C),' is activated at the same rate as native protein C by the soluble thrombomodulin-thrombin complex (6) . When protein C activation is carried out over endothelial cells, gla-domainless protein C is activated poorly, suggesting that in this setting a component other than thrombomodulin itself is required for rapid protein C activation (6) .
Coagulation Factor Va also accelerates the rate of protein C activation by thrombin; this activity is contained in the light chain of Factor Va (4). In the current study we have compared the activation of protein C in the presence of thrombomodulin with that in the presence of Factor Va light chain (FVa-LC) and have explored the possibility that thrombomodulin and Factor Va or its light chain act together to regulate protein C activation by thrombin.
Methods
Except where indicated, all chemicals were purchased from Sigma Chemical Co., St. Louis, MO. Human (3) and bovine protein C (7), 1. Abbreviations used in this paper: FVa-LC, Factor Va light chain; gladomainless protein C, chymotrypsin-treated protein C that lacks the amino-terminal 41 amino acids, including all of the y-carboxyglutamyl residues; protein Ca, activated protein C; S2238, D-Phe-pipecolyl-Argp-nitroanilide.
human (8) and bovine (9) Factor V, human (10) and bovine thrombin (1 1), rabbit thrombomodulin (2) , and human antithrombin III (12) were isolated as previously reported. The proteins used were all homogeneous as judged by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Gla-domainless protein C was prepared by limited proteolysis of bovine protein C with chymotrypsin (6) . Human (4) and bovine (9) FV1-LC were isolated from thrombin-activated Factor V by ion-exchange chromatography, as indicated. Protein C activation by thrombin (1-10 nM) in the presence of cofactors was carried out at 370C for 15 
Results
Direct comparison of the kinetic properties and requirements for protein C activation using thrombomodulin and FVa-LC containing 0.1 M NaCl, 2.5 mM CaCI2, and 5 mg/ml bovine serum albumin. Protein C activation was terminated using a final concentration of 40 U/ml hirudin and 350 ,g/ml antithrombin III, and the amount of protein C. assayed using S2338 as described in Methods. were initiated to determine how these two cofactors augment or regulate protein C activation. In the absence of either cofactor, thrombin activates protein C slowly. Using 1 nM human thrombin, protein C activation was accelerated from 0.01 mol/min per mol to 16 mol protein C./min per mol of thrombin by 2 nM thrombomodulin ( Fig. 1) . At a saturating concentration of human FVa-LC (90 nM), protein Ca formation was 20 times less rapid (0.75 mol protein C./min per mol of thrombin). At all protein C concentrations used, thrombomodulin caused a 20-fold greater acceleration of protein C activation than human FV.-LC. The activation of bovine protein C and bovine gladomainless protein C by thrombin in the presence of either cofactor was also compared. When thrombomodulin was varied from 0.25 to 1 nM in the presence of 10 nM bovine thrombin, the activation of intact and gla-domainless protein C was indistinguishable as shown in Fig. 2 A.2 When human FV.-LC was used as a cofactor instead of thrombomodulin, gla-domainless protein C was activated by human thrombin at only 5% the rate of intact protein C (Fig. 2 B) . A mixture of intact and gla-domainless protein C was activated by thrombin and human FV1-LC at the same rate as intact protein C, thus excluding the presence of an inhibitor to the FVa-LC in the gladomainless protein C preparation.
That thrombomodulin is 20 times more efficient than FVa-LC allowed us to study the effects of adding human FVa-LC on the thrombin-thrombomodulin-catalyzed activation of protein C. For these experiments we used conditions where FVa-LC contributed minimally to protein C activation (using 1 nM thrombin). FV1-LC in concentrations up to 25 nM had no effect on protein C activation by 2 nM thrombomodulin and 1 nM thrombin. However, at FVa-LC concentrations .30 nM there was significant reduction in the activity ofthe thrombin-thrombomodulin complex, and at 90 nM FV1-LC, complete inhibition was observed. Fig. 3 shows the inhibition of thrombin-thrombomodulin complex by 30 and 90 nM FVa-LC at different protein C concentrations. Increasing protein C concentration from 0.25 to 3 gM had no effect on the inhibitory activity of FVa-LC, suggesting that FV1-LC does not inhibit by binding protein C in place of the thrombin-thrombomodulin complex. Although FV.-LC did not stimulate activation of gla-domainless protein C, it did inhibit the ability of thrombomodulin to activate this molecule.
Inhibition of protein C activation could not be completely reversed by increasing thrombomodulin concentrations (2-128 nM), although at high thrombomodulin concentrations some acceleration of the rate of protein C activation was observed (Table I) . When the concentration ofboth thrombin and thrombomodulin were increased in the presence of inhibitory concentrations of FV1-LC, there was a linear increase in the rate of protein C activation. We were unable to completely overcome 2. Rabbit thrombomodulin is approximately twofold more active with bovine thrombin as compared with human thrombin using either native or gla-domainless protein C. the inhibition using up to 400 nM thrombin-thrombomodulin complex. We also studied whether thrombomodulin could inhibit FVa-LC-dependent protein C activation. We used con- (13) . Studies in patients with congenital Factor V deficiency would be difficult to interpret since these patients lack not only the potential protein C activating capacity of Factor Va but are also deficient in thrombin generation. We speculate that in the microvasculature, where endothelial cell density is great (14), thrombomodulin must be a major determinant of protein C activation.
Several distinct features of the two protein C activation systems are clearly resolved by this study. First, the activation of protein C by the thrombin-thrombomodulin complex and the FVa-LC in the presence of thrombin involves recognition of different structural features on the protein C molecule. Specifically, whereas FVa-LC requires the presence ofthe gla-domain, the thrombin-thrombomodulin complex does not. The 'y-carboxyl glutamyl residues in coagulation factors are considered to be calcium binding sites. The calcium-dependent activation of protein C by the thrombin-thrombomodulin complex is mediated via calcium binding to a gla-domain-independent site (15) . Our current results indicate that the region of protein C containing the y-carboxyglutamyl residues is involved in substrate recognition by the light chain and thrombin, but this involvement does not depend on calcium ions. Indeed, calcium binding to the gla-residues may inhibit protein C activation in the presence of light chain. High calcium ion concentrations (.7.5 mM) do inhibit the reaction (unpublished results).
These obvious differences between the two activation systems raise the question of whether the two activators might function synergistically. Previous studies had suggested possible synergistic interaction between thrombomodulin and an undefined component of the endothelial cell membrane (6) . Kinetic studies indicated that this component functioned by interacting through the gla-domain of protein C to decrease the Michaelis constant for protein C activation. Our finding that effective FVa-LCdependent activation of protein C is dependent on the gla-domain, is compatible with the hypothesis that the light chain provides this substrate binding site on the cell surface. Attempts to test this model in solution resulted in FVa-LC inhibition of thrombin-thrombomodulin catalyzed protein C activation. Al (16) leaving the FVa-LC behind. As the FVa-LC accumulates, inhibition of thrombomodulin activity could then result, preventing continued protein C activation once sufficient Factor Va has been inactivated. That the thrombin-thrombomodulin complex is subject to inhibition in vivo is suggested by experiments in dogs where it was shown that infusion of thrombin stimulated conversion of -10% of protein to C to Ca (17) .
When the thrombin infusion was stopped, plasma levels ofprotein Ca fell at the same rate as found when protein Ca itself was infused, implying that the thrombin-thrombomodulin complex was rapidly inhibited. The contribution of antithrombin III, FVa-LC, or other factors in the inactivation of the thrombinthrombomodulin complex in vivo is unknown. The studies provided here suggest the possibility of Factor Va involvement in the regulation of thrombomodulin activity. Further investigations ofthe physiological role ofFactor Va in protein C activation will have to be addressed in animal model experiments. Although the concentrations of proteins used in our studies are probably higher than those achieved in vivo, it must be remembered that protein C activation in vivo occurs on cell surface receptors where proteins are concentrated. The finding that human but not bovine Factor Va or the isolated light chain accelerates protein C activation by thrombin could explain the well-documented observation that Factor Va activity is rapidly lost during in vitro clotting of human but not bovine blood (18) .
